
Anti-Inhibitor Coagulant Complex (AICC) Lyophilized Powder
Form: Lyophilized Powder (Reconstituted for IV infusion)
Strength: 500 units, 1000 units, and 2500 units
Reference Brands: FEIBA(US)
Category: Blood Disorder
Anti-Inhibitor Coagulant Complex (AICC), such as FEIBA, is approved in the US by the FDA and in the EU via EMA for managing bleeding in hemophilia patients with inhibitors. Regulatory approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews comprehensive clinical and manufacturing information, while the EMA ensures compliance with regional safety and quality requirements. For guidance on dossier preparation, regulatory strategies, and market access, visit PharmaTradz. Ensuring regional compliance is essential for the safe, effective, and timely approval of AICC products worldwide, supporting optimal hemophilia patient care.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Prothrombin Complex Concentrate (PCC) injection
Strength: 250 IU to 300 IU
Form: Injection
Reference Brands: Kcentra (4-factor PCC), Bebulin VH (3-factor PCC)(US)
View Details Get EnquiryMesna Injection
Strength: 100 mg/mL
Form: Injection
Reference Brands: Mesnex(US)
View Details Get EnquiryLeucovorin tablets/Capsule
Strength: 15 mg, 50 mg
Form: Tablet/Capsules
Reference Brands: Folvite(US & EU)
View Details Get EnquiryPegfilgrastim injection
Strength: 6 mg per single-use syringe
Form: Injection
Reference Brands: Neulasta, Pelgraz(US)
View Details Get Enquiry